Evidence map›Paper›PMID 41626465›Full record

ArticleACS omega2026

Impact of Single Halogen Atom Substitutions on Antiviral Profile of Inhibitors Targeting SARS-CoV‑2 Main Protease.

Haydar Bulut, Nobuyo Higashi-Kuwata, Hiromi Ogata-Aoki, Hironori Hayashi, Nobutoki Takamune, Naoki Kishimoto, Debananda Das, Mi Li, Alexander Wlodawer, Shogo Misumi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Haydar BulutExperimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, United States.ORCID https://orcid.org/0000-0003-0262-6296
Nobuyo Higashi-KuwataDepartment of Refractory Viral Diseases, National Institute of Global Health and Medicine, Japan Institute for Health Security, Tokyo 162-8655, Japan.ORCID https://orcid.org/0000-0002-9404-3532
Hiromi Ogata-AokiDepartment of Refractory Viral Diseases, National Institute of Global Health and Medicine, Japan Institute for Health Security, Tokyo 162-8655, Japan.
Hironori HayashiInternational Research Institute of Disaster Science, Tohoku University, Miyagi 980-8575, Japan.
Nobutoki TakamuneDepartment of Environmental and Molecular Health Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0973, Japan.
Naoki KishimotoDepartment of Environmental and Molecular Health Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0973, Japan.
Debananda DasExperimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, United States.ORCID https://orcid.org/0000-0001-9943-5888
Mi LiBasic Science Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702, United States.
Alexander WlodawerLaboratory of Cell Biology, National Cancer Institute, Bethesda, Maryland 20892, United States.ORCID https://orcid.org/0000-0002-5510-9703
Shogo MisumiDepartment of Environmental and Molecular Health Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0973, Japan.
Hirokazu TamamuraDepartment of Medicinal Chemistry, Laboratory for Biomaterials and Bioengineering, Institute of Integrated Research, Institute of Science Tokyo, Tokyo 101-0062, Japan.ORCID https://orcid.org/0000-0003-2788-2579
Hiroaki MitsuyaExperimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The SARS-CoV-2 main protease (M

Identifiers

PMID41626465
PMCPMC12854628

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.